Healthcare’s Next Wave Is Getting More Personalized

Good morning, ! This week we’re diving into the precision medicine market size, Medtech VC funding overview, Oncology dominators competitive landscape, and the increasing number of health and fitness apps usage

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

DATA DIVE

Precision Medicine Stops Being Niche

Precision medicine is quietly becoming core healthcare infrastructure. The market is projected to grow from $87.5B in 2023 to $249.2B by 2030, driven by collapsing genomic sequencing costs, expanding AI-enabled analytics, and rising demand for therapies that actually work the first time.

The important shift is structural, not scientific. AI is rapidly becoming the operating layer that makes precision medicine scalable, particularly in oncology, where biomarker-driven treatment selection is replacing broad therapeutic guesswork. Precision oncology alone is expected to surpass $200B by 2030.

For investors and operators, the opportunity increasingly sits upstream. Not in individual tests, but in the platforms controlling genomic data, clinical workflows, and decision-support infrastructure. The winners will likely look less like diagnostics vendors and more like integrated healthcare operating systems.

The bottleneck remains execution. Interoperability, reimbursement, and workforce readiness still lag the technology curve. But the direction is increasingly clear: precision medicine is moving from specialty capability to default model for high-value care. (More)

HEALTHTECH CORNER

MedTech VC Isn’t Dead. It’s Repricing Risk.

MedTech venture funding is showing signs of stabilization, but the market looks fundamentally different from the 2021 peak. Global deal value climbed back toward $17B in 2025, while deal count continues to drift lower from its pandemic-era highs, according to PitchBook data. The signal is clear: capital is concentrating into fewer, more conviction-driven bets.

The reset matters because MedTech no longer benefits from the “growth at any price” dynamic that inflated digital health and connected-device valuations four years ago. Investors are now prioritizing reimbursement visibility, regulatory clarity, and integration into provider workflows over pure device novelty.

Wearables and remote monitoring remain attractive, but funding is increasingly flowing toward infrastructure-oriented platforms that can generate longitudinal clinical data, automate care pathways, or reduce labor intensity inside hospitals. Hardware alone is no longer enough.

The broader implication is that MedTech VC is shifting from experimentation to operational discipline. For founders, the bar is higher. For incumbents and strategics, the pullback may create one of the best acquisition environments since 2020. (More)

PRESENTED BY MODE MOBILE

One Shark Missed Billions… Another Saw This Coming

Imagine turning down Uber at a valuation of $10 million, only to watch it go public at over $80 billion.

That’s exactly what happened to Mark Cuban… a 799,900% return, gone.

But original Shark Tank investor Kevin Harrington built his career doing the opposite: spotting asymmetric opportunities before they go mainstream.

Like Uber turned vehicles into income-generating assets, Mode Mobile is turning smartphones into income streams.

They were named the #1 fastest-growing software company by Deloitte and have already helped their users earn and save over $1B.

Kevin Harrington invested early.

And at just $0.52/share, you can still get in before their potential IPO.

Secure shares at $0.52 while the pre-IPO window is still open.

_

Potential Uber return for Marc Cuban does not take into account dilution.

The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period in 2023.

Please read the offering circular at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A Offering.

COMPETITIVE LANDSCAPE SNAPSHOT

TREND TO WATCH

The Post-Pandemic Wellness Boom Is Becoming Healthcare Infrastructure

Health and fitness applications are no longer a pandemic-era consumer habit. They are becoming a durable layer of healthcare delivery.

Global downloads of health and fitness apps climbed from 188.7M between 2010 and 2013 to 877.4M between 2020 and 2025, according to the European Society of Medicine. The sharpest acceleration came after COVID, when remote care, behavioral tracking, and digital engagement shifted from optional convenience to normalized healthcare behavior.

The key shift now is strategic. The market is moving beyond step counters and calorie logs toward clinically adjacent platforms tied to chronic disease management, mental health, preventive care, and remote patient monitoring.

That changes the buyer landscape entirely. Employers, payers, providers, and pharma companies increasingly view mobile health apps as low-cost engagement infrastructure rather than standalone wellness products.

The next phase will likely favor platforms with measurable outcomes, reimbursement pathways, and integration into broader care ecosystems. Consumer engagement alone is no longer enough.

Why it matters: As healthcare systems face mounting labor shortages and rising chronic disease burden, scalable digital engagement tools are becoming operational necessities, not lifestyle accessories. The companies that survive this cycle will be the ones that can prove retention, outcomes, and clinical utility. (More)

"Don’t be distracted by criticism. Remember, the only taste of success some people get is to take a bite out of you."

Zig Ziglar